Mazalvix (Mesalazine)

Mesalazine inhibits the cyclooxygenase and lipoxygenase pathways in the colonic lining, lowering the production of prostaglandins and leukotrienes. This suppression of pro‑inflammatory mediators reduces neutrophil activation, cytokine release, and oxidative stress, thereby limiting tissue injury and promoting healing of the intestinal mucosa.

The dosage of Mazalvix is individualized by the prescribing clinician based on disease severity, extent, and patient response. Healthcare professionals determine the appropriate amount, frequency, and duration of therapy in accordance with local prescribing guidelines and the patient’s clinical condition.

Safety data for mesalazine during pregnancy and lactation are limited. The product should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Clinicians should discuss the uncertainty with the patient and consider alternative therapies when appropriate.

To request Mazalvix, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Mazalvix delivers mesalazine directly to the rectal mucosa, offering a targeted approach for distal ulcerative colitis. Compared with oral 5‑ASA formulations, rectal delivery can achieve higher local concentrations with reduced systemic exposure, which may lower the risk of systemic side effects while providing effective symptom control.

Store Mazalvix at room temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and avoid exposure to extreme temperatures. Follow any additional handling instructions provided on the label to maintain product integrity.

Mazalvix is a rectal formulation intended for local application. The prescribed dose is inserted into the rectum using the supplied applicator or as directed by the healthcare professional. Patients should follow the administration instructions carefully to ensure optimal drug contact with the affected mucosa.

Serious adverse events include severe allergic reactions such as anaphylaxis, pancreatitis, blood dyscrasias (e.g., neutropenia or agranulocytosis), and hepatotoxicity. Patients should be instructed to seek immediate medical attention if they experience symptoms such as rash, difficulty breathing, persistent abdominal pain, jaundice, or unexplained fatigue.

Mazalvix should be avoided in individuals with a known hypersensitivity to mesalazine or any other 5‑ASA compounds. It is also contraindicated in patients with severe renal or hepatic impairment where the risk of toxicity outweighs potential benefit, and in those for whom rectal administration is not feasible.